| Market Cap | 60.17M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -8.39M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | -43.00% |
| Sales | 10.52M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -59.00% |
| Dividend | N/A | Price/Book | 1.34 | EPS next 5Y | - | 52W High Chg | -77.00% |
| Recommedations | - | Quick Ratio | 5.22 | Shares Outstanding | 41.20M | 52W Low Chg | 17.00% |
| Insider Own | - | ROA | -10.50% | Shares Float | 383.12M | Beta | 0.76 |
| Inst Own | - | ROE | -22.25% | Shares Shorted/Prior | -/- | Price | 1.34 |
| Gross Margin | -11.03% | Profit Margin | -79.79% | Avg. Volume | 1,995 | Target Price | - |
| Oper. Margin | -12.89% | Earnings Date | Feb 28 | Volume | 3,100 | Change | -0.74% |
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom. It is also involved in the development of DEP cabazitaxel that is in Phase 2 clinical trial for the treatment of prostate and other cancers, DEP docetaxel that is in Phase 2 clinical trials for the treatment of colorectal and other cancers, DEP irinotecan that is in Phase 2 clinical trials f for the treatment of pancreatic and other cancers; and EP gemcitabine, DEP HER-2 ADC, and DEP HER-2 radiotherapy completed preclinical trials for the treatment of solid cancers. In addition, the company's DEP radiotheranostics development pipeline includes DEP HER2-zirconium, a HER2-targeted radio diagnostic for HER2-positive cancers, such as breast and gastric cancer; and HER2-targeted DEP SN38 ADC, a targeted ADC therapeutic for the treatment of human ovarian cancer. Starpharma Holdings Limited was incorporated in 1997 and is headquartered in Abbotsford, Australia.